Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV

Launched by PT BIO FARMA · Apr 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how long the immune response lasts after receiving two different typhoid vaccines, Bio TCV and PQed TCV, in people from Indonesia. Typhoid fever is a serious illness caused by bacteria that can spread through contaminated food and water. The researchers want to see how well these vaccines protect against typhoid fever over the long term after just one dose.

To participate in the trial, you need to be healthy and able to give consent (or have a parent or guardian who can). The study is open to individuals aged 18 and older. If you join, you will receive either of the vaccines and will be monitored for your immune response over time. It’s important to note that people with certain blood disorders cannot participate. The trial is not yet recruiting, but it aims to provide valuable information on vaccine effectiveness to help protect against typhoid fever in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy
• • Subject/Parents/legal guardian(s) have been informed properly regarding the study and signed the informed consent form/and informed assent form.
• • Subject/parents/legal guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial.
• Exclusion Criteria:
• • History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.